Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR

BACKGROUND: Considering cell cycle dependent cytotoxicity, intercalation of chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) may be a treatment option in non-small cell lung cancer (NSCLC). This randomized phase 2 study compared the efficacy of paclitaxel and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Choi, Yoon Ji, Lee, Dae Ho, Choi, Chang Min, Lee, Jung Shin, Lee, Seung Jin, Ahn, Jin-Hee, Kim, Sang-We
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4619194/
https://ncbi.nlm.nih.gov/pubmed/26493267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1714-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky